Clinerion Adds Patient Network Explorer Coverage to Three New Hospitals in Brazil
The three newest Brazilian hospitals to join the global community of partner hospitals on Clinerion’s Patient Network Explorer platform are:
- Santa Casa de Misericórdia, Belo Horizonte, Minas Gerais
- Hospital Tacchini, Bento Gonçalves, Rio Grande do Sul
- UOPECCAN – União Oeste Paranaense de Estudos e Combate ao Câncer, also known as the Hospital do Câncer, Cascavel, Paraná
The hospital network in Brazil comprises hospitals of varied sizes, locations, and specializations.
Through Patient Network Explorer, patients in Brazil are visible to international clinical trials sponsors, increasing the likelihood of their hospital being selected as a trial site and their being accepted to join trials of next generation treatments.
Read more about this announcement here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
